GLP-1 receptor agonistsmedicines such as semaglutide and liraglutideare increasingly prescribed for type 2 diabetes and weight management, but many survivors wonder whether these treatments are safe given their cancer history
For oral GHK-Cu, follow the serving size on the product label
The entire premise of a study relies on the compound being exactly what it purports to be
However, it is important to recognise that patients prescribed Mounjaro often have underlying conditions such as type 2 diabetes, obesity, metabolic syndrome, or non-alcoholic fatty liver disease (NAFLD), all of which are independently associated with elevated ferritin levels
29 This practice aligns perfectly with GLP-1 therapy
This drug may cause side effects, including nausea/vomiting, change in bowel movements, including diarrhea or constipation, abdominal pain, headache, and fatigue